Foment Bio

About the offering

Foment Bio is a biopharmaceutical company developing a novel, non-viral, off-the-shelf transient gene therapy platform to treat cardiometabolic dysfunction. Foment’s transient gene therapy aims to drive regenerative exosome production in vivo (inside the body) to prevent cell death, decrease inflammation, reduce fibrosis, and restore microvasculature. Foment’s approach has demonstrated clinical safety and observed signals of efficacy in multiple phase 2 FDA studies with over 200 patients treated to date. The Foment platform addresses multiple multi-billion-dollar markets and presents a potential near-term revenue opportunity in the companion animal space. REASONS TO INVEST Reasons Icon Pioneering Non-Viral Gene Therapy Approach – Unlike traditional gene or stem cell therapies, Foment Bio’s transient gene therapy aims to offer a simpler manufacturing process that is scalable, cost-effective, and repeat-dosing capable solution for driving tissue repair and restoring organ function via in vivo exosome production. Reasons Icon Large and Growing Multi-Billion-Dollar Markets – In the United States, millions of dogs & cats suffer from heart failure and chronic kidney disease stemming from cardiometabolic dysfunction. In humans, cardiometabolic disease affects tens of millions, with markets for chronic kidney disease ($48B by 2032), heart failure ($34B by 2030), and wound healing presenting significant revenue opportunities. Reasons Icon Accelerated Revenue Strategy: Companion Animal Market – while the Foment platform has enormous potential in human indications, development in the companion animal space offers the potential for near term commercialization. Companion animal market revenue will support human clinical development and reduce future capital needs. the pitch Cardiometabolic disease due to obesity, high cholesterol, sugar, and inflammation is affecting over half the US population. Sadly, similar levels of cardiometabolic dysfunction also plague our pets as millions of cats & dogs suffer from heart failure and chronic kidney disease in their elder years with few treatment options available. At Foment Bio we are developing a transient gene therapy platform to stimulate natural regenerative healing that can remodel tissue and restore organ function. Our off-the-shelf, injectable solution aims to offers a safe, scalable, and cost-effective alternative to traditional cell-based therapies. With a clear regulatory path, experienced leadership, and a growing market, Foment Bio aims to bring innovative regenerative medicine to companion animal health. the PROBLEM & our SOLUTION The Problem Approximately 1 in 10 dogs will develop heart disease in their lifetime (Source) while chronic kidney disease (CKD) affects 10% of dogs and 35% of cats in older populations. Available treatment options focus primarily on symptom management rather than disease modification. For the millions of animals that suffer from these conditions in the U.S. alone, pet owners can spend $1,000–$5,000 per year on ineffective care and symptom control. The veterinary market lacks a therapeutic option that addresses the underlying biological causes of HF or CKD. Our Solution Foment’s non-viral gene therapy induces transient exosome production in vivo, triggering natural repair processes that reduce inflammation, prevent cell death, restore vasculature and improve organ function. As exosome release has been identified as the primary mechanism behind the benefits of regenerative cell therapy, many groups are attempting to go downstream of the cell and manufacturing exosomes as therapeutic products. Our approach is unique: by simply delivering plasmid constructs, we are providing temporary instructions and leveraging the evolutionarily optimized exosome production capabilities of the cells within the tissue. Unlike cell-based or viral gene therapies, Foment gene therapy is stable, scalable, and perhaps most importantly, affordable. Thus, we believe, Foment’s therapy will be an accessible, off-the-shelf treatment option for veterinarians and pet owners everywhere. the MARKET & our TRACTION The companion animal health market is experiencing significant growth globally. Reaching $27.4 billion in 2024, it is projected to exceed $55 billion by 2033 (Source). Heart failure & chronic kidney disease represent major market needs, with millions of pets affected and limited treatment options available. Foment Bio's Traction: 200 patients treated with FB-101 across multiple FDA Phase 2 studies: demonstrated safety & observed efficacy signals in multiple indications Preclinical heart failure models show FB-201 tissue preservation and function recovery Established robust portfolio of intellectual property with sublicense rights Strategic discussions with leading veterinary pharmaceutical companies Planned FB-201 pilot dog study initiation in 2025 Competitors & our DIFFERENTIATION Main Competitors: Hill’s Prescription Diet & Royal Canin (dietary management solutions) Generic phosphate binders & supplements What Makes Us Different: Unlike dietary solutions that only manage symptoms, our approach is designed to stimulate repair and remodel tissue at the molecular level. True revascularization and tissue remodeling can substantially alter the trajectory of the disease, restore organ function and preserve quality of life. ACHIEVEMENTS & RECOGNITION Validated regenerative science, with over 200 human patient treatments showing clinical safety Exclusive sublicense rights to key intellectual property Preclinical studies demonstrate regenerative benefits in animal models WHy invest Foment Bio is introducing a novel regenerative therapy for companion animal heart failure & kidney disease, addressing a major unmet need in a growing market. With strong scientific foundation, and strategic industry partnerships, we believe we are well-positioned to advance veterinary medicine. Join us in shaping the future of regenerative healing for pets.

FAQ